Contents

Series Introduction (Murray Weiner) .................................................. v
Preface .................................................................................. vii
Contributors ..........................................................................

Part I Characterization of Peripheral Dopamine Receptors ............. 1

1 Functional Models for and Characteristics of DA_1 and DA_2
Dopamine Receptors in the Periphery ........................................... 3
Jai D. Kohli and Leon I. Goldberg

2 Affinities of Dopamine Agonists and Antagonists for
Peripheral Dopamine Receptors ............................................. 27
Otto-Erich Brodde

Part II Inhibition of Sympathetic Neurotransmission by
Dopaminergic Agonists .......................................................... 75

3 Effect of Rigid and Nonrigid Analogs of Dopamine on
Vascular Neurotransmission ................................................... 77
Odd S. Steinsland, J. Paul Hieble, and Sharon H. Nelson
4 Inhibition of Cardiac Neurotransmission In Vivo and In Vitro by Structural Analogs of Dopamine  
Page 103

5 Cardiac and Vascular Consequences of Modulation of Sympathetic Neurotransmission by Dopamine Receptor Agonists  
Mustafa F. Lokhandwala, Majd H. Sabouni, and Karim A. Alkadhi  
Page 133

Part III Cardiovascular Effects of Selective Dopamine Receptor Agonists in Experimental Animals  
Page 151

6 The Pentobarbital-Anesthesized Rat: Cardiovascular Mechanisms of Action of DA1 and DA2 Receptor Agonists  
Icilio Cavero  
Page 153

7 Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on the Intact Animal  
J. Paul Hieble, David A. A. Owen, Alan L. Blumberg, Lewis B. Kinter, Robert M. DeMarinis, and Carol A. Harvey  
Page 177

8 Peripheral Dopaminergic Agonist Activity of Aminoethylindolones and Related Compounds  
Robert M. DeMarinis and J. Paul Hieble  
Page 205

9 Cardiovascular Activity of Ergoline Derivatives  
Richard A. Hahn  
Page 229

10 Inhibition of Dopamine β-Hydroxylase to Increase Dopaminergic Tone In Vivo  
Eliot H. Ohlstein, Lawrence I. Kruse, Lewis B. Kinter, and Barry A. Berkowitz  
Page 255

Part IV Dopamine Receptors in Man: Therapeutic Applications  
Page 279

11 Clinical Utility of Cardiovascular Agents Acting on the Dopamine Receptor  
Leon I. Goldberg and Jai D. Kohli  
Page 281
Contents

12 Dopaminergic Control of Aldosterone Secretion 297
   Robert M. Carey

13 Hemodynamic Activity of N-n-propyl-N-n-Butyldopamine 315
   Addison A. Taylor and William H. Fennell

14 Clinical Effects of Fenoldopam, a Potent Dopamine (DA₁) Agonist 331
   Thomas R. Beck, Annette Clancy, and Robin J. Cregeen

Index 345